What disease does durvalumab/Infinifer treat?

Durvalumab/Infinifer (Durvalumab) is an immune checkpoint inhibitor mainly used to treat a variety of malignant tumors. As a PD-L1 inhibitor, durvalumab relieves the inhibitory effect of the immune system and enhances the body's immune response, thereby helping the patient's immune system recognize and attack cancer cells. It has been approved to treat many types of cancer, especially those with advanced or metastatic cancer that do not respond well to conventional treatments.

Impartumab is particularly important in the treatment of lung cancer, especially for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In the treatment of non-small cell lung cancer, durvalumab is usually used in combination with chemotherapy to help patients delay disease progression and improve survival rates. In addition, it has also shown certain efficacy in the treatment of endometrial cancer, cholangiocarcinoma, liver cancer, bladder cancer and other tumors.

For small cell lung cancer, durvalumab as an immunotherapy provides a new treatment option, especially for those patients with metastasis or recurrence. The application of immune checkpoint inhibitors marks a new era of immunotherapy in cancer treatment. It activates immune cells in patients and improves the immune system's ability to recognize cancer cells, thereby inhibiting the growth of cancer.

In addition to lung cancer and other common tumors, durvalumab has shown promise against certain cancer types with immune evasion properties. For example, in the treatment of cholangiocarcinoma and liver cancer, it helps patients cope with the tumor's immune evasion mechanism by enhancing the activity of T cells, thereby improving the therapeutic effect.

To sum up, durvalumab, as an innovative immunotherapy drug, provides new treatment options for patients with multiple cancer types. Especially for patients whose response to traditional treatments is unsatisfactory, immunotherapy is undoubtedly an important breakthrough.

Reference materials: https://www.imfinzi.com/